vs
Side-by-side financial comparison of Dominari Holdings Inc. (DOMH) and ZEVRA THERAPEUTICS, INC. (ZVRA). Click either name above to swap in a different company.
ZEVRA THERAPEUTICS, INC. is the larger business by last-quarter revenue ($34.1M vs $30.1M, roughly 1.1× Dominari Holdings Inc.). On growth, Dominari Holdings Inc. posted the faster year-over-year revenue change (220.4% vs 183.4%). Over the past eight quarters, Dominari Holdings Inc.'s revenue compounded faster (369.1% CAGR vs 215.7%).
Zevra Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients with rare under-treated orphan diseases, with a primary focus on central nervous system and metabolic rare disorder segments. Its main target markets are North America and the European Union.
DOMH vs ZVRA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $30.1M | $34.1M |
| Net Profit | $-131.8M | — |
| Gross Margin | — | — |
| Operating Margin | -8.9% | 27.3% |
| Net Margin | -438.1% | — |
| Revenue YoY | 220.4% | 183.4% |
| Net Profit YoY | -12426.2% | — |
| EPS (diluted) | $-6.94 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $30.1M | $34.1M | ||
| Q3 25 | $50.8M | $26.1M | ||
| Q2 25 | $34.1M | $25.9M | ||
| Q1 25 | $8.1M | $20.4M | ||
| Q4 24 | $9.4M | $12.0M | ||
| Q3 24 | $4.0M | $3.7M | ||
| Q2 24 | $6.2M | $4.4M | ||
| Q1 24 | $1.4M | $3.4M |
| Q4 25 | $-131.8M | — | ||
| Q3 25 | $125.2M | $-544.0K | ||
| Q2 25 | $16.6M | $74.7M | ||
| Q1 25 | $-32.5M | $-3.1M | ||
| Q4 24 | $1.1M | — | ||
| Q3 24 | $-4.2M | $-33.2M | ||
| Q2 24 | $-6.1M | $-19.9M | ||
| Q1 24 | $-5.4M | $-16.6M |
| Q4 25 | -8.9% | 27.3% | ||
| Q3 25 | -3.1% | 15.9% | ||
| Q2 25 | -57.0% | -274.5% | ||
| Q1 25 | -394.6% | -26.3% | ||
| Q4 24 | 0.4% | -128.0% | ||
| Q3 24 | -79.1% | -739.0% | ||
| Q2 24 | -44.3% | -534.8% | ||
| Q1 24 | -205.2% | -598.1% |
| Q4 25 | -438.1% | — | ||
| Q3 25 | 246.4% | -2.1% | ||
| Q2 25 | 48.7% | 288.7% | ||
| Q1 25 | -400.5% | -15.2% | ||
| Q4 24 | 11.4% | — | ||
| Q3 24 | -104.2% | -899.2% | ||
| Q2 24 | -99.1% | -447.9% | ||
| Q1 24 | -398.0% | -485.3% |
| Q4 25 | $-6.94 | — | ||
| Q3 25 | $7.27 | $-0.01 | ||
| Q2 25 | $1.12 | $1.21 | ||
| Q1 25 | $-3.02 | — | ||
| Q4 24 | $0.21 | — | ||
| Q3 24 | $-0.67 | $-0.69 | ||
| Q2 24 | $-1.01 | $-0.48 | ||
| Q1 24 | $-0.91 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $80.5M | $62.4M |
| Total DebtLower is stronger | — | $61.9M |
| Stockholders' EquityBook value | $69.4M | $154.7M |
| Total Assets | $112.9M | $284.7M |
| Debt / EquityLower = less leverage | — | 0.40× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.5M | $62.4M | ||
| Q3 25 | $176.2M | $54.4M | ||
| Q2 25 | $28.2M | $47.7M | ||
| Q1 25 | $18.9M | $37.3M | ||
| Q4 24 | $8.2M | $33.8M | ||
| Q3 24 | $7.2M | $54.0M | ||
| Q2 24 | $12.1M | $39.3M | ||
| Q1 24 | $7.1M | $42.8M |
| Q4 25 | — | $61.9M | ||
| Q3 25 | — | $61.3M | ||
| Q2 25 | — | $60.7M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $59.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $69.4M | $154.7M | ||
| Q3 25 | $210.2M | $133.2M | ||
| Q2 25 | $88.6M | $117.2M | ||
| Q1 25 | $42.4M | $41.0M | ||
| Q4 24 | $39.9M | $39.7M | ||
| Q3 24 | $38.3M | $69.8M | ||
| Q2 24 | $42.4M | $32.5M | ||
| Q1 24 | $47.7M | $48.8M |
| Q4 25 | $112.9M | $284.7M | ||
| Q3 25 | $223.4M | $270.1M | ||
| Q2 25 | $109.3M | $256.3M | ||
| Q1 25 | $52.3M | $172.7M | ||
| Q4 24 | $47.1M | $178.1M | ||
| Q3 24 | $43.4M | $191.6M | ||
| Q2 24 | $49.1M | $144.4M | ||
| Q1 24 | $52.2M | $151.3M |
| Q4 25 | — | 0.40× | ||
| Q3 25 | — | 0.46× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.50× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $22.7M | $5.5M |
| Free Cash FlowOCF − Capex | — | $5.5M |
| FCF MarginFCF / Revenue | — | 16.1% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-2.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.7M | $5.5M | ||
| Q3 25 | $-4.9M | $4.7M | ||
| Q2 25 | $-353.0K | $-3.6M | ||
| Q1 25 | $1.2M | $-8.2M | ||
| Q4 24 | $-16.7M | $-16.3M | ||
| Q3 24 | $-4.7M | $-18.1M | ||
| Q2 24 | $1.4M | $-19.1M | ||
| Q1 24 | $-8.6M | $-16.2M |
| Q4 25 | — | $5.5M | ||
| Q3 25 | — | $4.2M | ||
| Q2 25 | — | $-3.8M | ||
| Q1 25 | — | $-8.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 16.1% | ||
| Q3 25 | — | 15.9% | ||
| Q2 25 | — | -14.7% | ||
| Q1 25 | — | -40.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 2.1% | ||
| Q2 25 | — | 0.8% | ||
| Q1 25 | — | 0.5% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | -0.04× | — | ||
| Q2 25 | -0.02× | -0.05× | ||
| Q1 25 | — | — | ||
| Q4 24 | -15.65× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOMH
| Chief Operating Decision Maker | $30.1M | 100% |
| Commissions | $458.0K | 2% |
ZVRA
| MIPLYFFA | $26.4M | 77% |
| Arimoclomol Purchase Agreement | $5.7M | 17% |
| Other | $2.0M | 6% |
